Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma

Journal of Clinical Oncology

Volumn 11, Issue 4, 1993, Pages 623-629

  Campbell, Laura A ^b   Seeger, Robert C ^b   Harris, Richard E ^b   Villablanca, Judith G ^b   Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG MIXTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MUCOSA INFLAMMATION; NEUROBLASTOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOXORUBICIN; ETOPOSIDE; HUMAN; INFANT; INFUSIONS, INTRAVENOUS; NEUROBLASTOMA; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0027522739     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1993.11.4.623     Document Type: Article

References (22)

1. August CS, Serota FT, Koch PA, et al: Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 2:609-616, 1984
2. Pinkerton CR, Philip T, Biron P, et al: High dose melphalan. vincristine, and total body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoma: A phase II study. Med Pediatr Oncol 15:236-240, 1987
3. Seeger RC, Moss TJ. Feig SA, et al: Bone marrow transplan-tation for poor prognosis neuroblastoma, in Evans AE, D'Angio GJ, Knudson AG, et al (eds): Advances in Neuroblastoma Research 2. New York, NY, Liss, 1988, pp 203-213
4. Seeger RC, Villablanca JG, Matthay KK, et al: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 366:527-534, 1991
5. Graham-Pole J, Casper J, Elfenbein G, et al: High dose chemoradiotherapy for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:152-158, 1991
6. Kushner BH, O'Reilly RJ, Mandell LR, et al: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9:274-279, 1991
7. Hartman O, Benhamou E, Beaujean F, et al: High dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A phase II study. J Clin Oncol 4:1804-1810, 1986
8. Cheung NKV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma J Clin Oncol 9:1050-1058, 1991
9. Bowman LC, Hancock ML, Santana VM, et al: Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St. Jude Children's Hospital experience, 1962 to 1988. J Clin Oncol 9:1599-1608, 1991
10. Carli M, Green AA, Hayes Fa, et al: Therapeutic efficacy of single drugs for childhood neuroblastoma: A review, in Raybaud C, Clement R, Lebreuil G, et al (eds): Proceedings, XIII Meeting of the International Society of Pediatric Oncology, ICS 570. Amsterdam, the Netherlands, Exerpta Medica, 1982, pp 141-150
11. Kellie SJ, De Kraker J, Lilleyman JS, et al: Ifosfamide in previously untreated disseminated neuroblastoma. Eur J Cancer Clin Oncol 24:903-908, 1988
12. Nissen NI, Pajak TF, Leone LA, et al: Clinical trial of VP 16-213 (NSC 141540) IV twice weekly in advanced neoplastic disease: A study by the Cancer and Leukemia Group B. Cancer 45:232-235, 1980
13. Richardson RL, Hahn RG, Kvols LK, et al: Bleomycin, etoposide, and continuous cisplatin in metastatic testicular cancer. Proc Am Soc Clin Oncol 4:105, 1985 (abstr)
14. Creagan ET, Richarson RL, Kovach JS: Pilot study of a continuous 5-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol 6: 1197-1201, 1988
15. Posner M, Skarin AT, Clark J, et al: Phase 1 study of continousinfusion cisplatin. Cancer Treat Rep 70:847-850, 1986
16. Salem P, Khalyl M, Jabbourty K, et al: Cis-diamminodichloroplatinum (11) by 5-day continuous infusion: A new dose schedule with minimal toxicity. Cancer 53:837-840, 1984
17. Castello MA, Dominici C, Clerico A: A pilot study of 5-day continuous infusion of high-dose cisplatin and pulsed etoposide in childhood solid tumors. Am J Pediatr Hematol Oncol 10:103-108, 1988
18. Reece PA, Stafford I, Abbott RL, et al: Two- versus 24-hour infusion of cisplatin: Pharmacokinetic considerations. J Clin Oncol 7:270-275, 1989
19. Vogelzang NJ: Continuous infusion chemotherapy: A critical review. J Clin Oncol 2:1289-1304, 1984
20. Neglia JP, Woods WG: Continuous-infusion doxoruicin in the treatment of primary hepatic malignancies of childhood. Cancer Treat Rep 70:655-657, 1986
21. Speth PA, Linssen PC, Holdrinet RS, et al: Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six hour continuous infusion. Clin Pharmacol Ther 41:661-665, 1987
22. Slevin ML, Clark PI, Osborne RJ, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide to small cell lung cancer. Proc Am Soc Clin Oncol 5:175, 1986 (abstr)